Medicofarma Biotech Sa Stock Total Debt

MDB Stock   0.41  0.03  7.89%   
Medicofarma Biotech SA fundamentals help investors to digest information that contributes to Medicofarma Biotech's financial success or failures. It also enables traders to predict the movement of Medicofarma Stock. The fundamental analysis module provides a way to measure Medicofarma Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Medicofarma Biotech stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Medicofarma Biotech SA Company Total Debt Analysis

Medicofarma Biotech's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Total Debt

 = 

Bonds

+

Notes

More About Total Debt | All Equity Analysis
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Competition

Based on the latest financial disclosure, Medicofarma Biotech SA has a Total Debt of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Biotechnology & Medical Research (which currently averages 0.0) industry. The total debt for all Poland stocks is 100.0% higher than that of the company.

Did you try this?

Run FinTech Suite Now

   

FinTech Suite

Use AI to screen and filter profitable investment opportunities
All  Next Launch Module

About Medicofarma Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Medicofarma Biotech SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medicofarma Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medicofarma Biotech SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with Medicofarma Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medicofarma Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medicofarma Biotech will appreciate offsetting losses from the drop in the long position's value.

Moving together with Medicofarma Stock

  0.68VEE Vee SAPairCorr
The ability to find closely correlated positions to Medicofarma Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medicofarma Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medicofarma Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medicofarma Biotech SA to buy it.
The correlation of Medicofarma Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medicofarma Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medicofarma Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medicofarma Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Medicofarma Stock Analysis

When running Medicofarma Biotech's price analysis, check to measure Medicofarma Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medicofarma Biotech is operating at the current time. Most of Medicofarma Biotech's value examination focuses on studying past and present price action to predict the probability of Medicofarma Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medicofarma Biotech's price. Additionally, you may evaluate how the addition of Medicofarma Biotech to your portfolios can decrease your overall portfolio volatility.